The FDA lists an ongoing Class II recall of vancomycin injection USP in 0.9% sodium chloride, 1 g per 200 mL (5 mg/mL), in single-dose GALAXY containers from Baxter Healthcare, recorded on 9 September 2026. The stated reason is deviation from current good manufacturing practice; the notice does not describe a specific contaminant or a reported patient harm.
Class II covers products where exposure may cause temporary or medically reversible effects, or where serious harm is unlikely. It is administrative and quality-related rather than a new safety signal about vancomycin itself.
For prescribers and pharmacists the practical step is a stock check. Whether these containers are distributed in India is not stated; their availability here is unknown.
- Ask pharmacy to check stock for Baxter premixed vancomycin 1 g/200 mL lots named in the recall.
- Switch to an alternative presentation for affected lots; dosing and monitoring do not change.
- Continue vancomycin AUC- or trough-guided monitoring as usual.
- Report any suspected adverse reaction linked to affected product.
Why it matters
Premixed vancomycin is widely used in hospitals, and a stock check prevents use of affected lots.
Don't overread it
A Class II manufacturing recall is not a safety signal about vancomycin as a drug.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free